No. | Drug-indication pair | Indication uniqueness | Disease rarity | Disease severity | Adv.tech. | Manufacturing technology | Therapeutic alternative | Sci. evid. clin.eff | Benefits from use of medicine | Cost effectiveness | Budget impact | Total number of points |
---|---|---|---|---|---|---|---|---|---|---|---|---|
 | THRESHOLD | 75 % |  |  |  |  |  |  |  |  |  | 15 points |
1 | Nexavar (HCC) | 1 | 2 | 2 | 0 | 2 | 2 | 2 | 0 | 1 | 1 | 13 |
2 | Nplate | 2 | 1 | 0 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 13 |
3 | Cystadane | 2 | 2 | 2 | 0 | 0 | 2 | 0 | 2 | 0 | 2 | 12 |
4 | Increlex | 2 | 0 | 0 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 12 |
5 | Revlimid (MM/S) | 1 | 0 | 2 | 1 | 0 | 2 | 2 | 1 | 1 | 2 | 12 |
6 | Yondelis | 1 | 1 | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 11 |
7 | Somavert | 2 | 1 | 1 | 2 | 2 | 0 | 1 | 1 | 1 | 0 | 11 |
8 | Tasigna | 2 | 2 | 2 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 10 |
9 | Torisel | 1 | 0 | 2 | 2 | 2 | 0 | 1 | 1 | 0 | 1 | 10 |
 | THRESHOLD | 50 % |  |  |  |  |  |  |  |  |  | 10 points |
10 | Vidaza | 1 | 0 | 2 | 1 | 0 | 0 | 2 | 1 | 1 | 0 | 8 |
11 | Atriance | 1 | 0 | 2 | 1 | 0 | 2 | 1 | 0 | 0 | 1 | 8 |
12 | Nexavar (RCC) | 1 | 0 | 2 | 0 | 2 | 1 | 2 | 0 | 0 | 0 | 8 |
 | THRESHOLD | 25 % |  |  |  |  |  |  |  |  |  | 5 points |